These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8818990)

  • 1. Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog.
    Dow J; Francesco GF; Berg C
    J Pharm Sci; 1996 Jul; 85(7):685-9. PubMed ID: 8818990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
    Sanwald P; David M; Dow J
    Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humans.
    Dow J; Berg C
    Chirality; 1995; 7(5):342-8. PubMed ID: 7495640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1.
    Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
    Biopharm Drug Dispos; 1999 Jan; 20(1):29-39. PubMed ID: 10086835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers.
    Dempsey E; Bourque S; Spénard J; Landriault H
    J Clin Pharmacol; 1996 Oct; 36(10):903-10. PubMed ID: 8930777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
    Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
    Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects.
    Shah A; Lanman R; Bhargava V; Weir S; Hahne W
    Biopharm Drug Dispos; 1995 Apr; 16(3):177-89. PubMed ID: 7787130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects.
    Boxenbaum H; Gillespie T; Heck K; Hahne W
    Biopharm Drug Dispos; 1993 Mar; 14(2):131-41. PubMed ID: 8453023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects.
    Boxenbaum H; Gillespie T; Heck K; Hahne W
    Biopharm Drug Dispos; 1992 Dec; 13(9):693-701. PubMed ID: 1467456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction.
    Stubbs K; Martin LA; Dimmitt DC; Pready N; Hahne WF
    J Clin Pharmacol; 1997 Oct; 37(10):926-36. PubMed ID: 9505984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate.
    Dimmitt DC; Hunt TL; Spalitto AJ; Cramer MB; Shah AK; Arumugham T; Hahne W
    Ann Pharmacother; 1998 Jan; 32(1):39-44. PubMed ID: 9475818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling.
    Sanwald-Ducray P; Dow J
    Xenobiotica; 1997 Feb; 27(2):189-201. PubMed ID: 9058532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women.
    Keung AC; Landriault H; Lefebvre M; Gossard D; Dempsey EE; Juneau M; Dimmitt D; Castles M; Roberts L; Spenard J
    Biopharm Drug Dispos; 1997 May; 18(4):361-9. PubMed ID: 9158883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of food on the bioavailability of dolasetron mesylate tablets.
    Lippert C; Keung A; Arumugham T; Eller M; Hahne W; Weir S
    Biopharm Drug Dispos; 1998 Jan; 19(1):17-9. PubMed ID: 9510981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2.
    Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
    Biopharm Drug Dispos; 1999 Jan; 20(1):41-8. PubMed ID: 10086836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy.
    Lippert CL; Dimmitt DC; Martin L; Cramer MB; Plezia P; Hahne WF
    Am J Ther; 1999 May; 6(3):129-35. PubMed ID: 10423655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children.
    Lerman J; Sims C; Sikich N; Gow R; Chin C; Dempsey E; Howard DR; Keung AC
    Clin Pharmacol Ther; 1996 Nov; 60(5):485-92. PubMed ID: 8941021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats.
    Herndon AK; Quimby JM; Sieberg LG; Davis L; Caress AL; Ligas S; Hansen RJ; Wittenburg LA; Gustafson DL
    J Feline Med Surg; 2018 Aug; 20(8):721-727. PubMed ID: 28905667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist.
    Reith MK; Sproles GD; Cheng LK
    Drug Metab Dispos; 1995 Aug; 23(8):806-12. PubMed ID: 7493546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.